1
|
Pascual G, Majem B, Benitah SA. Targeting lipid metabolism in cancer metastasis. Biochim Biophys Acta Rev Cancer 2024; 1879:189051. [PMID: 38101461 DOI: 10.1016/j.bbcan.2023.189051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 11/29/2023] [Accepted: 12/04/2023] [Indexed: 12/17/2023]
Abstract
This review delves into the most recent research on the metabolic adaptability of cancer cells and examines how their metabolic functions can impact their progression into metastatic forms. We emphasize the growing significance of lipid metabolism and dietary lipids within the tumor microenvironment, underscoring their influence on tumor progression. Additionally, we present an outline of the interplay between metabolic processes and the epigenome of cancer cells, underscoring the importance regarding the metastatic process. Lastly, we examine the potential of targeting metabolism as a therapeutic approach in combating cancer progression, shedding light on innovative drugs/targets currently undergoing preclinical evaluation.
Collapse
Affiliation(s)
- Gloria Pascual
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
| | - Blanca Majem
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
| | - Salvador Aznar Benitah
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
| |
Collapse
|
2
|
Majem B, Naqvi I, Dennis C, Dailey L, Clish CB, Kalaany N. Abstract PO-029: Pancreatic cancer-associated cachexia as a 3-stage systemic disease with changes in body composition, tissue-specific wasting across time and alterations in glucose metabolism. Cancer Res 2021. [DOI: 10.1158/1538-7445.panca21-po-029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease that rapidly deteriorates the organism resulting in <10% 5-years survival in humans. Cancer-associated cachexia (CAC) is a multi-organ complex syndrome that accompanies PDAC in 85% of the cases. CAC is often characterized by the loss of body weight, including loss of muscle and fat tissues. Chronic inflammation, myokines and adipokines (released from muscle and fat, respectively), together with few recent tumor-derived factors, have been shown to collectively induce some of the metabolic changes in peripheral tissues that lead to wasting. Those include the synthesis of acute phase proteins in the liver, lipolysis and browning of the white adipose tissues (WAT), and protein degradation in the skeletal muscle. However, how these changes affect systemic metabolism, such as amino-acid utilization for liver gluconeogenesis, the systemic consequences of increased free fatty acids from lipolysis and their final destination for b-oxidation, or the rewiring of glucose metabolism, are processes not fully understood during cachexia. Here we established a 3-stage model of cachexia progression, including pre-, early- and late-CAC stages, in a doxycycline inducible murine model of PDAC (p48(Cre/+);tetKRAS(LSL/+);p53(fl/fl)), in both genders. We have monitored body weight loss, changes in body composition using DEXA scan, food intake and survival, across time since the start of doxycycline administration (i.e. tumor initiation). We have submitted these mice to metabolic cages aiming to distinguish in which of the 3 stages fat consumption starts, as well as monitored the weight of 8 tissue types (pancreas, liver, iWAT, eWAT, brown adipose tissue, quadriceps, gastrocnemius and soleus) over time. Overall, we have defined pre-CAC as “weight-gaining stage, before body weight peaks”, early-CAC as <10% and late-CAC as >10% of body weight loss, together with specific changes in body composition in each stage, food intake only happening at the very end stage, while all non-tumoral tissues present significant reduced weight at early stages. We have performed metabolomics and lipidomics in all peripheral tissues, aiming to identify changes that occur not only at early- but also at the pre-CAC stages, when pancreatic tumors already weighed more than double of the normal pancreas. In addition, glucose tolerance test analyses showed that tumor-bearing mice cleared the glucose more rapidly than control mice, even at pre-CAC stages, opening new avenues to continue studying glucose metabolism in the periphery such as increased liver gluconeogenesis and peripheral insulin resistance. Together, these results allowed us to establish a murine model to study cachexia in 3 stages, similar to what happens in humans. Furthermore, metabolomic data from the peripheral tissues, tumor interstitial fluid (TIF) and plasma, will allow us to identify the metabolic landscape of the entire organism throughout the progression of the disease, and potentially propose new therapeutic windows to target or prevent wasting in cancer.
Citation Format: Blanca Majem, Insia Naqvi, Courtney Dennis, Lucas Dailey, Clary B. Clish, Nada Kalaany. Pancreatic cancer-associated cachexia as a 3-stage systemic disease with changes in body composition, tissue-specific wasting across time and alterations in glucose metabolism [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-029.
Collapse
Affiliation(s)
- Blanca Majem
- 1Boston Children's Hospital, Harvard Medical School, Boston, MA,
| | - Insia Naqvi
- 1Boston Children's Hospital, Harvard Medical School, Boston, MA,
| | - Courtney Dennis
- 2Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA
| | - Lucas Dailey
- 2Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA
| | - Clary B. Clish
- 2Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA
| | - Nada Kalaany
- 1Boston Children's Hospital, Harvard Medical School, Boston, MA,
| |
Collapse
|
3
|
Masanas M, Masiá N, Suárez‐Cabrera L, Olivan M, Soriano A, Majem B, Devis‐Jauregui L, Burgos‐Panadero R, Jiménez C, Rodriguez‐Sodupe P, Boloix A, Toledano I, Guillén G, Navarro A, Llobet‐Navas D, Villanueva A, Sánchez de Toledo J, Roma J, Noguera R, Moreno L, Krauss R, Gallego S, Santamaria A, Segura MF. The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Clin Transl Med 2021; 11:e533. [PMID: 34709738 PMCID: PMC8516339 DOI: 10.1002/ctm2.533] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Revised: 07/21/2021] [Accepted: 07/29/2021] [Indexed: 11/07/2022] Open
Affiliation(s)
- Marc Masanas
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Nuria Masiá
- Cell Cycle and Cancer LaboratoryBiomedical Research Group in UrologyVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Leticia Suárez‐Cabrera
- Cell Cycle and Cancer LaboratoryBiomedical Research Group in UrologyVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Mireia Olivan
- Cell Cycle and Cancer LaboratoryBiomedical Research Group in UrologyVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
- Translational Oncology LaboratoryAnatomy UnitDepartment of Pathology and Experimental TherapySchool of MedicineUniversitat de Barcelona (UB)L'Hospitalet de LlobregatSpain
| | - Aroa Soriano
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Blanca Majem
- Cell Cycle and Cancer LaboratoryBiomedical Research Group in UrologyVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Laura Devis‐Jauregui
- Molecular Mechanisms and Experimental Therapy in Oncology‐Oncobell ProgramBellvitge Biomedical Research Institute (IDIBELL)L'Hospitalet de LlobregatSpain
| | - Rebeca Burgos‐Panadero
- Group of Translational Research in Pediatric Solid Tumors Department of PathologyMedical SchoolUniversity of Valencia‐INCLIVA Biomedical Health Research InstituteValenciaSpain
- Low Prevalence Tumors. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)Instituto de Salud Carlos IIIMadridSpain
| | - Carlos Jiménez
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | | | - Ariadna Boloix
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Ignasi Toledano
- Cell Cycle and Cancer LaboratoryBiomedical Research Group in UrologyVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Gabriela Guillén
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
- Department of SurgeryUniversitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Alexandra Navarro
- Department of PathologyVall d'Hebron University HospitalUniversitat Autònoma de BarcelonaBarcelonaSpain
| | - David Llobet‐Navas
- Molecular Mechanisms and Experimental Therapy in Oncology‐Oncobell ProgramBellvitge Biomedical Research Institute (IDIBELL)L'Hospitalet de LlobregatSpain
- Low Prevalence Tumors. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)Instituto de Salud Carlos IIIMadridSpain
| | - Alberto Villanueva
- Group of Chemoresistance and Predictive FactorsSubprogram Against Cancer Therapeutic Resistance (ProCURE)ICOOncobell ProgramIDIBELLL'Hospitalet del LlobregatBarcelonaSpain
- Xenopat S.L., Business BioincubatorBellvitge Health Science CampusBarcelonaSpain
| | - Josep Sánchez de Toledo
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
- Catalan Institute of Oncology (ICO)BarcelonaSpain
| | - Josep Roma
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Rosa Noguera
- Group of Translational Research in Pediatric Solid Tumors Department of PathologyMedical SchoolUniversity of Valencia‐INCLIVA Biomedical Health Research InstituteValenciaSpain
- Low Prevalence Tumors. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)Instituto de Salud Carlos IIIMadridSpain
| | - Lucas Moreno
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
- Pediatric Oncology and Hematology DepartmentHospital Universitari Vall d'Hebron ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | | | - Soledad Gallego
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
- Pediatric Oncology and Hematology DepartmentHospital Universitari Vall d'Hebron ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Anna Santamaria
- Cell Cycle and Cancer LaboratoryBiomedical Research Group in UrologyVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Miguel F. Segura
- Group of Translational Research in Child and Adolescent CancerVall d'Hebron Research Institute (VHIR) ‐ Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| |
Collapse
|
4
|
Parrilla A, Barber M, Majem B, Castellví J, Morote J, Sánchez JL, Pérez-Benavente A, Segura MF, Gil-Moreno A, Santamaria A. Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. Cancers (Basel) 2020; 12:E886. [PMID: 32268485 PMCID: PMC7226261 DOI: 10.3390/cancers12040886] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 04/02/2020] [Accepted: 04/03/2020] [Indexed: 12/12/2022] Open
Abstract
Identifying novel actionable factors that critically contribute to tumorigenesis is essential in ovarian cancer, an aggressive and disseminative tumor, with limited therapeutic options available. Here we show that Aurora Borealis (BORA), a mitotic protein that plays a key role in activating the master mitotic kinase polo-like kinase 1 (PLK1), has an oncogenic role in ovarian cancer. Gain and loss of function assays on mouse models and ex vivo patient-derived ascites cultures revealed an oncogenic role of BORA in tumor development and a transcriptome-analysis in clinically representative models depicted BORA's role in survival, dissemination and inflammatory cancer related-pathways. Importantly, combinatory treatments of FDA-approved inhibitors against oncogenic downstream effectors of BORA displayed synergistic effect in ovarian cancer models, offering promising therapeutic value. Altogether, our findings uncovered for the first time a critical role of BORA in the viability of human cancer cells providing potential novel therapeutic opportunities for ovarian cancer management.
Collapse
Affiliation(s)
- Alfonso Parrilla
- Group of Biomedical Research in Urology, Cell Cycle and Cancer Laboratory, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; (A.P.); (M.B.); (B.M.); (J.M.)
| | - Marta Barber
- Group of Biomedical Research in Urology, Cell Cycle and Cancer Laboratory, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; (A.P.); (M.B.); (B.M.); (J.M.)
| | - Blanca Majem
- Group of Biomedical Research in Urology, Cell Cycle and Cancer Laboratory, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; (A.P.); (M.B.); (B.M.); (J.M.)
| | - Josep Castellví
- Department of Pathology, Vall Hebron University Hospital, 08035 Barcelona, Spain;
| | - Juan Morote
- Group of Biomedical Research in Urology, Cell Cycle and Cancer Laboratory, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; (A.P.); (M.B.); (B.M.); (J.M.)
- Department of Urology, Vall Hebron University Hospital, 08035 Barcelona, Spain
| | - José Luis Sánchez
- Group of Biomedical Research in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), CIBERONC, 08035 Barcelona, Spain; (J.L.S.); (A.P.-B.); (A.G.-M.)
- Department of Gynecology, Vall Hebron University Hospital, 08035 Barcelona, Spain
| | - Asunción Pérez-Benavente
- Group of Biomedical Research in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), CIBERONC, 08035 Barcelona, Spain; (J.L.S.); (A.P.-B.); (A.G.-M.)
- Department of Gynecology, Vall Hebron University Hospital, 08035 Barcelona, Spain
| | - Miguel F. Segura
- Group of Translational Research in Child and Adolescent Cancer, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain;
| | - Antonio Gil-Moreno
- Group of Biomedical Research in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), CIBERONC, 08035 Barcelona, Spain; (J.L.S.); (A.P.-B.); (A.G.-M.)
- Department of Gynecology, Vall Hebron University Hospital, 08035 Barcelona, Spain
| | - Anna Santamaria
- Group of Biomedical Research in Urology, Cell Cycle and Cancer Laboratory, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; (A.P.); (M.B.); (B.M.); (J.M.)
| |
Collapse
|
5
|
Majem B, Nadal E, Muñoz-Pinedo C. Exploiting metabolic vulnerabilities of Non small cell lung carcinoma. Semin Cell Dev Biol 2019; 98:54-62. [PMID: 31238096 DOI: 10.1016/j.semcdb.2019.06.004] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Revised: 06/16/2019] [Accepted: 06/17/2019] [Indexed: 12/20/2022]
Abstract
Lung cancer is the main cause of cancer death worldwide. Non-Small Cell Lung Carcinoma (NSCLC) is the most common subtype of lung cancer, and the prognosis of NSCLC patients in advanced stages is still very poor. Given the need for new therapies, the metabolism of NSCLC has been widely studied in the past two decades to identify vulnerabilities that could be translated into novel anti-metabolic therapeutic approaches. A number of studies have highlighted the role of glucose and mitochondrial metabolism in the development of NSCLC. The metabolic properties of lung tumors have been characterized in detail in vivo, and they include high glucose and lactate use and high heterogeneity regarding the use of nutrients and mitochondrial pathways. This heterogeneity has also been observed in patients infused with labeled nutrients. We will summarize here the knowledge about the use of amino acids, fatty acids and carbohydrates in NSCLC that could lead to new combination treatments.
Collapse
Affiliation(s)
- Blanca Majem
- Cell Death Regulation Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Spain.
| | - Ernest Nadal
- Clinical Research in Solid Tumors (CReST) Group, Oncobell Program, IDIBELL, L'Hospitalet, Spain; Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet, Spain.
| | - Cristina Muñoz-Pinedo
- Cell Death Regulation Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Spain.
| |
Collapse
|
6
|
Parrilla A, Majem B, Barber M, Olivan M, Tamayo G, Castellví J, Pérez A, Gil-Moreno A, Santamaria A. PO-048 Therapeutic relevance of the cell cycle protein BORA in cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.92] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
7
|
Li F, Kaczor-Urbanowicz KE, Sun J, Majem B, Lo HC, Kim Y, Koyano K, Rao SL, Kang SY, Kim SM, Kim KM, Kim S, Chia D, Elashoff D, Grogan TR, Xiao X, Wong DTW. Characterization of Human Salivary Extracellular RNA by Next-generation Sequencing. Clin Chem 2018; 64:1085-1095. [PMID: 29685897 DOI: 10.1373/clinchem.2017.285072] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 03/28/2018] [Indexed: 11/06/2022]
Abstract
BACKGROUND It was recently discovered that abundant and stable extracellular RNA (exRNA) species exist in bodily fluids. Saliva is an emerging biofluid for biomarker development for noninvasive detection and screening of local and systemic diseases. Use of RNA-Sequencing (RNA-Seq) to profile exRNA is rapidly growing; however, no single preparation and analysis protocol can be used for all biofluids. Specifically, RNA-Seq of saliva is particularly challenging owing to high abundance of bacterial contents and low abundance of salivary exRNA. Given the laborious procedures needed for RNA-Seq library construction, sequencing, data storage, and data analysis, saliva-specific and optimized protocols are essential. METHODS We compared different RNA isolation methods and library construction kits for long and small RNA sequencing. The role of ribosomal RNA (rRNA) depletion also was evaluated. RESULTS The miRNeasy Micro Kit (Qiagen) showed the highest total RNA yield (70.8 ng/mL cell-free saliva) and best small RNA recovery, and the NEBNext library preparation kits resulted in the highest number of detected human genes [5649-6813 at 1 reads per kilobase RNA per million mapped (RPKM)] and small RNAs [482-696 microRNAs (miRNAs) and 190-214 other small RNAs]. The proportion of human RNA-Seq reads was much higher in rRNA-depleted saliva samples (41%) than in samples without rRNA depletion (14%). In addition, the transfer RNA (tRNA)-derived RNA fragments (tRFs), a novel class of small RNAs, were highly abundant in human saliva, specifically tRF-4 (4%) and tRF-5 (15.25%). CONCLUSIONS Our results may help in selection of the best adapted methods of RNA isolation and small and long RNA library constructions for salivary exRNA studies.
Collapse
Affiliation(s)
- Feng Li
- Institute of Diagnostic in Chinese Medicine, Hunan University of Chinese Medicine, Hunan, China.,Center for Oral/Head & Neck Oncology Research, School of Dentistry, University of California at Los Angeles, Los Angeles, CA
| | - Karolina Elżbieta Kaczor-Urbanowicz
- Center for Oral/Head & Neck Oncology Research, School of Dentistry, University of California at Los Angeles, Los Angeles, CA.,Department of Orthodontics, School of Dentistry, University of California at Los Angeles, Los Angeles, CA
| | - Jie Sun
- Medical School of Shenzhen University, Shenzhen, Guangdong, China
| | - Blanca Majem
- Biomedical Research Unit in Gynecology, Vall d'Hebron Research Institute (VHIR) and University Hospital, University Autonoma of Barcelona (UAB), Barcelona, Spain
| | - Hsien-Chun Lo
- Department of Integrative Biology and Physiology, University of California at Los Angeles, Los Angeles, CA
| | - Yong Kim
- Center for Oral/Head & Neck Oncology Research, School of Dentistry, University of California at Los Angeles, Los Angeles, CA
| | - Kikuye Koyano
- Department of Integrative Biology and Physiology, University of California at Los Angeles, Los Angeles, CA
| | - Shannon Liu Rao
- Center for Oral/Head & Neck Oncology Research, School of Dentistry, University of California at Los Angeles, Los Angeles, CA
| | - So Young Kang
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Su Mi Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Kyoung-Mee Kim
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Sung Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - David Chia
- Department of Pathology & Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA
| | - David Elashoff
- Department of Biostatistics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA
| | - Tristan R Grogan
- Department of Biostatistics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA
| | - Xinshu Xiao
- Department of Integrative Biology and Physiology, University of California at Los Angeles, Los Angeles, CA
| | - David T W Wong
- Center for Oral/Head & Neck Oncology Research, School of Dentistry, University of California at Los Angeles, Los Angeles, CA; .,Department of Biomedical Engineering, School of Engineering, University of California at Los Angeles, Los Angeles, CA.,Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.,Department of Head and Neck Surgery/Otolaryngology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA
| |
Collapse
|
8
|
Rapado-González Ó, Majem B, Muinelo-Romay L, Álvarez-Castro A, Santamaría A, Gil-Moreno A, López-López R, Suárez-Cunqueiro MM. Human salivary microRNAs in Cancer. J Cancer 2018; 9:638-649. [PMID: 29556321 PMCID: PMC5858485 DOI: 10.7150/jca.21180] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Accepted: 12/11/2017] [Indexed: 12/25/2022] Open
Abstract
Circulating microRNAs (miRNAs) have emerged as excellent candidates for cancer biomarkers. Several recent studies have highlighted the potential use of saliva for the identification of miRNAs as novel biomarkers, which represents a great opportunity to improve diagnosis and monitor general health and disease. This review summarises the mechanisms of miRNAs deregulation in cancer, the value of targeting them with a therapeutic intention and the evidence of the potential clinical use of miRNAs expressed in saliva for the detection of different cancer types. We also provide a comprehensive review of the different methods for normalising the levels of specific miRNAs present in saliva, as this is a critical step in their analysis, and the challenge to validate salivary miRNAs as a reality to manage cancer patients.
Collapse
Affiliation(s)
- Óscar Rapado-González
- Department of Surgery and Medical Surgical Specialties, Medicine and Dentistry School, University of Santiago de Compostela, Spain. Health Research Institute of Santiago (IDIS); Santiago de Compostela, Spain.,Liquid Biopsy Analysis Unit, Translational Medical Oncology, Health Research Institute of Santiago (IDIS), CIBERONC, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Blanca Majem
- Cell Cycle and Cancer Lab, Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Laura Muinelo-Romay
- Liquid Biopsy Analysis Unit, Translational Medical Oncology, Health Research Institute of Santiago (IDIS), CIBERONC, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Ana Álvarez-Castro
- Medical Digestive Service, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS); Santiago de Compostela, Spain
| | - Anna Santamaría
- Cell Cycle and Cancer Lab, Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Antonio Gil-Moreno
- Cell Cycle and Cancer Lab, Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.,Department of Gynecology Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Rafael López-López
- Liquid Biopsy Analysis Unit, Translational Medical Oncology, Health Research Institute of Santiago (IDIS), CIBERONC, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - María Mercedes Suárez-Cunqueiro
- Department of Surgery and Medical Surgical Specialties, Medicine and Dentistry School, University of Santiago de Compostela, Spain. Health Research Institute of Santiago (IDIS); Santiago de Compostela, Spain
| |
Collapse
|
9
|
Rosso M, Majem B, Devis L, Lapyckyj L, Besso MJ, Llauradó M, Abascal MF, Matos ML, Lanau L, Castellví J, Sánchez JL, Pérez Benavente A, Gil-Moreno A, Reventós J, Santamaria Margalef A, Rigau M, Vazquez-Levin MH. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS One 2017. [PMID: 28934230 DOI: 10.1371/journal.pone.0184439] [] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Ovarian cancer (OC) is the fifth cancer death cause in women worldwide. The malignant nature of this disease stems from its unique dissemination pattern. Epithelial-to-mesenchymal transition (EMT) has been reported in OC and downregulation of Epithelial cadherin (E-cadherin) is a hallmark of this process. However, findings on the relationship between E-cadherin levels and OC progression, dissemination and aggressiveness are controversial. In this study, the evaluation of E-cadherin expression in an OC tissue microarray revealed its prognostic value to discriminate between advanced- and early-stage tumors, as well as serous tumors from other histologies. Moreover, E-cadherin, Neural cadherin (N-cadherin), cytokeratins and vimentin expression was assessed in TOV-112, SKOV-3, OAW-42 and OV-90 OC cell lines grown in monolayers and under anchorage-independent conditions to mimic ovarian tumor cell dissemination, and results were associated with cell aggressiveness. According to these EMT-related markers, cell lines were classified as mesenchymal (M; TOV-112), intermediate mesenchymal (IM; SKOV-3), intermediate epithelial (IE; OAW-42) and epithelial (E; OV-90). M- and IM-cells depicted the highest migration capacity when grown in monolayers, and aggregates derived from M- and IM-cell lines showed lower cell death, higher adhesion to extracellular matrices and higher invasion capacity than E- and IE-aggregates. The analysis of E-cadherin, N-cadherin, cytokeratin 19 and vimentin mRNA levels in 20 advanced-stage high-grade serous human OC ascites showed an IM phenotype in all cases, characterized by higher proportions of N- to E-cadherin and vimentin to cytokeratin 19. In particular, higher E-cadherin mRNA levels were associated with cancer antigen 125 levels more than 500 U/mL and platinum-free intervals less than 6 months. Altogether, E-cadherin expression levels were found relevant for the assessment of OC progression and aggressiveness.
Collapse
Affiliation(s)
- Marina Rosso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Blanca Majem
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Laura Devis
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Lara Lapyckyj
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María José Besso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Marta Llauradó
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - María Florencia Abascal
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María Laura Matos
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Lucia Lanau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Josep Castellví
- Pathology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - José Luis Sánchez
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Antonio Gil-Moreno
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Jaume Reventós
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Anna Santamaria Margalef
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Marina Rigau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Mónica Hebe Vazquez-Levin
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| |
Collapse
|
10
|
Rosso M, Majem B, Devis L, Lapyckyj L, Besso MJ, Llauradó M, Abascal MF, Matos ML, Lanau L, Castellví J, Sánchez JL, Pérez Benavente A, Gil-Moreno A, Reventós J, Santamaria Margalef A, Rigau M, Vazquez-Levin MH. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS One 2017. [PMID: 28934230 DOI: 10.1371/journal.pone.0184439]+[] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Ovarian cancer (OC) is the fifth cancer death cause in women worldwide. The malignant nature of this disease stems from its unique dissemination pattern. Epithelial-to-mesenchymal transition (EMT) has been reported in OC and downregulation of Epithelial cadherin (E-cadherin) is a hallmark of this process. However, findings on the relationship between E-cadherin levels and OC progression, dissemination and aggressiveness are controversial. In this study, the evaluation of E-cadherin expression in an OC tissue microarray revealed its prognostic value to discriminate between advanced- and early-stage tumors, as well as serous tumors from other histologies. Moreover, E-cadherin, Neural cadherin (N-cadherin), cytokeratins and vimentin expression was assessed in TOV-112, SKOV-3, OAW-42 and OV-90 OC cell lines grown in monolayers and under anchorage-independent conditions to mimic ovarian tumor cell dissemination, and results were associated with cell aggressiveness. According to these EMT-related markers, cell lines were classified as mesenchymal (M; TOV-112), intermediate mesenchymal (IM; SKOV-3), intermediate epithelial (IE; OAW-42) and epithelial (E; OV-90). M- and IM-cells depicted the highest migration capacity when grown in monolayers, and aggregates derived from M- and IM-cell lines showed lower cell death, higher adhesion to extracellular matrices and higher invasion capacity than E- and IE-aggregates. The analysis of E-cadherin, N-cadherin, cytokeratin 19 and vimentin mRNA levels in 20 advanced-stage high-grade serous human OC ascites showed an IM phenotype in all cases, characterized by higher proportions of N- to E-cadherin and vimentin to cytokeratin 19. In particular, higher E-cadherin mRNA levels were associated with cancer antigen 125 levels more than 500 U/mL and platinum-free intervals less than 6 months. Altogether, E-cadherin expression levels were found relevant for the assessment of OC progression and aggressiveness.
Collapse
Affiliation(s)
- Marina Rosso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Blanca Majem
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Laura Devis
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Lara Lapyckyj
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María José Besso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Marta Llauradó
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - María Florencia Abascal
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María Laura Matos
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Lucia Lanau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Josep Castellví
- Pathology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - José Luis Sánchez
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Antonio Gil-Moreno
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Jaume Reventós
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Anna Santamaria Margalef
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Marina Rigau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Mónica Hebe Vazquez-Levin
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| |
Collapse
|
11
|
Rosso M, Majem B, Devis L, Lapyckyj L, Besso MJ, Llauradó M, Abascal MF, Matos ML, Lanau L, Castellví J, Sánchez JL, Pérez Benavente A, Gil-Moreno A, Reventós J, Santamaria Margalef A, Rigau M, Vazquez-Levin MH. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS One 2017; 12:e0184439. [PMID: 28934230 PMCID: PMC5608212 DOI: 10.1371/journal.pone.0184439] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2017] [Accepted: 08/23/2017] [Indexed: 12/21/2022] Open
Abstract
Ovarian cancer (OC) is the fifth cancer death cause in women worldwide. The malignant nature of this disease stems from its unique dissemination pattern. Epithelial-to-mesenchymal transition (EMT) has been reported in OC and downregulation of Epithelial cadherin (E-cadherin) is a hallmark of this process. However, findings on the relationship between E-cadherin levels and OC progression, dissemination and aggressiveness are controversial. In this study, the evaluation of E-cadherin expression in an OC tissue microarray revealed its prognostic value to discriminate between advanced- and early-stage tumors, as well as serous tumors from other histologies. Moreover, E-cadherin, Neural cadherin (N-cadherin), cytokeratins and vimentin expression was assessed in TOV-112, SKOV-3, OAW-42 and OV-90 OC cell lines grown in monolayers and under anchorage-independent conditions to mimic ovarian tumor cell dissemination, and results were associated with cell aggressiveness. According to these EMT-related markers, cell lines were classified as mesenchymal (M; TOV-112), intermediate mesenchymal (IM; SKOV-3), intermediate epithelial (IE; OAW-42) and epithelial (E; OV-90). M- and IM-cells depicted the highest migration capacity when grown in monolayers, and aggregates derived from M- and IM-cell lines showed lower cell death, higher adhesion to extracellular matrices and higher invasion capacity than E- and IE-aggregates. The analysis of E-cadherin, N-cadherin, cytokeratin 19 and vimentin mRNA levels in 20 advanced-stage high-grade serous human OC ascites showed an IM phenotype in all cases, characterized by higher proportions of N- to E-cadherin and vimentin to cytokeratin 19. In particular, higher E-cadherin mRNA levels were associated with cancer antigen 125 levels more than 500 U/mL and platinum-free intervals less than 6 months. Altogether, E-cadherin expression levels were found relevant for the assessment of OC progression and aggressiveness.
Collapse
Affiliation(s)
- Marina Rosso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Blanca Majem
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Laura Devis
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Lara Lapyckyj
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María José Besso
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Marta Llauradó
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - María Florencia Abascal
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - María Laura Matos
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
| | - Lucia Lanau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Josep Castellví
- Pathology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - José Luis Sánchez
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Antonio Gil-Moreno
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
- Gynecology Oncology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Jaume Reventós
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Anna Santamaria Margalef
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Marina Rigau
- Biomedical Research Unit in Gynecology, Vall Hebron Research Institute and University Hospital, Barcelona, Spain
| | - Mónica Hebe Vazquez-Levin
- Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina
- * E-mail: ,
| |
Collapse
|
12
|
Majem B, Parrilla A, Soriano A, Gil-Moreno A, Segura M, Santamaria A. Functional characterization of a tumor suppressor micro-RNA in ovarian cancer. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61374-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Laurent LC, Abdel-Mageed AB, Adelson PD, Arango J, Balaj L, Breakefield X, Carlson E, Carter BS, Majem B, Chen CC, Cocucci E, Danielson K, Courtright A, Das S, Abd Elmageed ZY, Enderle D, Ezrin A, Ferrer M, Freedman J, Galas D, Gandhi R, Huentelman MJ, Van Keuren-Jensen K, Kalani Y, Kim Y, Krichevsky AM, Lai C, Lal-Nag M, Laurent CD, Leonardo T, Li F, Malenica I, Mondal D, Nejad P, Patel T, Raffai RL, Rubio R, Skog J, Spetzler R, Sun J, Tanriverdi K, Vickers K, Wang L, Wang Y, Wei Z, Weiner HL, Wong D, Yan IK, Yeri A, Gould S. Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. J Extracell Vesicles 2015; 4:26533. [PMID: 26320937 PMCID: PMC4553263 DOI: 10.3402/jev.v4.26533] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2014] [Revised: 04/17/2015] [Accepted: 05/03/2015] [Indexed: 01/14/2023] Open
Abstract
Extracellular RNAs (exRNAs) have been identified in all tested biofluids and have been associated with a variety of extracellular vesicles, ribonucleoprotein complexes and lipoprotein complexes. Much of the interest in exRNAs lies in the fact that they may serve as signalling molecules between cells, their potential to serve as biomarkers for prediction and diagnosis of disease and the possibility that exRNAs or the extracellular particles that carry them might be used for therapeutic purposes. Among the most significant bottlenecks to progress in this field is the lack of robust and standardized methods for collection and processing of biofluids, separation of different types of exRNA-containing particles and isolation and analysis of exRNAs. The Sample and Assay Standards Working Group of the Extracellular RNA Communication Consortium is a group of laboratories funded by the U.S. National Institutes of Health to develop such methods. In our first joint endeavour, we held a series of conference calls and in-person meetings to survey the methods used among our members, placed them in the context of the current literature and used our findings to identify areas in which the identification of robust methodologies would promote rapid advancements in the exRNA field.
Collapse
Affiliation(s)
- Louise C Laurent
- Division of Maternal Fetal Medicine, Department of Reproductive Medicine, University of California San Diego, San Diego, CA, USA.,Sanford Consortium for Regenerative Medicine, San Diego, CA, USA;
| | - Asim B Abdel-Mageed
- Department of Urology, Tulane University, School of Medicine, New Orleans, LA, USA
| | | | | | - Leonora Balaj
- Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.,Program in Neuroscience, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - Xandra Breakefield
- Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.,Program in Neuroscience, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.,Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - Elizabeth Carlson
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - Bob S Carter
- Center for Theoretical and Applied Neuro-Oncology, Division of Neurosurgery, University of California San Diego, San Diego, CA, USA
| | - Blanca Majem
- School of Dentistry, University of California, Los Angeles, CA, USA
| | - Clark C Chen
- Center for Theoretical and Applied Neuro-Oncology, Division of Neurosurgery, University of California San Diego, San Diego, CA, USA
| | - Emanuele Cocucci
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA
| | - Kirsty Danielson
- Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Amanda Courtright
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - Saumya Das
- Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | | | | | | | - Marc Ferrer
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Bethesda, MD, USA
| | - Jane Freedman
- Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
| | - David Galas
- Pacific Northwest Diabetes Research Institute, Seattle, WA, USA.,Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Roopali Gandhi
- Department of Neurology, Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | | | | | - Yong Kim
- School of Dentistry, University of California, Los Angeles, CA, USA
| | - Anna M Krichevsky
- Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Charles Lai
- Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.,Program in Neuroscience, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - Madhu Lal-Nag
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Bethesda, MD, USA
| | - Clara D Laurent
- Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Trevor Leonardo
- Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Feng Li
- School of Dentistry, University of California, Los Angeles, CA, USA
| | - Ivana Malenica
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - Debasis Mondal
- Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, USA
| | - Parham Nejad
- Department of Neurology, Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Tushar Patel
- Department of Transplantation, Mayo Clinic Florida, Jacksonville, FL, USA.,Department of Cancer Biology, Mayo Clinic Florida, Jacksonville, FL, USA
| | - Robert L Raffai
- Department of Surgery, University of California San Francisco, San Francisco, CA, USA.,Department of Veteran's Affairs, San Francisco, CA, USA
| | - Renee Rubio
- Center for Cancer Computational Biology, Dana Farber Cancer Institute, Boston, MA, USA
| | | | | | - Jie Sun
- School of Dentistry, University of California, Los Angeles, CA, USA
| | - Kahraman Tanriverdi
- Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
| | - Kasey Vickers
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN, USA.,Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Liang Wang
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Yaoyu Wang
- Center for Cancer Computational Biology, Dana Farber Cancer Institute, Boston, MA, USA
| | - Zhiyun Wei
- Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Howard L Weiner
- Department of Neurology, Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - David Wong
- School of Dentistry, University of California, Los Angeles, CA, USA
| | - Irene K Yan
- Department of Cancer Biology, Mayo Clinic Florida, Jacksonville, FL, USA
| | - Ashish Yeri
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - Stephen Gould
- Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD, USA
| |
Collapse
|
14
|
Rosso M, Majem B, Devis L, Lapyckyj L, Llauradó M, Lanau L, Abascal MF, Matos ML, Besso MJ, Castellví J, Sanchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Reventós J, Rigau M, Vazquez-Levin M. Abstract 4093: Cadherin “switch” and ovarian cancer: Studies using in vitro models and patient samples. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-4093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Ovarian cancer (OC) is the 5th leading cause of cancer deaths in women worldwide due to late symptoms and its diagnosis at advanced stages. Epithelial to mesenchymal transition (EMT) is an important step in cancer invasion/metastasis and downregulation of Epithelial cadherin (Ecad) is a critical feature of this process. Ecad expression was evaluated in 100 OC tissue sections, finding a decreased Ecad signal along tumor stage, with highest expression in stage I/II (no invasive) and lowest in stage IV (invasive) tumors. These results are in agreement with previous reports showing reduced Ecad expression in correlation with poor prognosis in OC patients. In some cases, Ecad downregulation is accompanied by increased Neural cadherin (Ncad) expression and acquisition of migratory/mesenchymal features. Although this cadherin “switch” has been reported in OC, current data is inconclusive. Expression of Ecad, Ncad and other EMT markers was studied in 4 OC cell lines and according to their levels they were classified as epithelial (OV90), intermediate epithelial (OAW42), intermediate mesenchymal (SKOV3) and mesenchymal (TOV112) cells. The mechanisms underlying regulation of Ecad levels were evaluated by assessing expression of its transcriptional repressors Twist, Snail, Slug, Zeb1. Migration properties were also studied, being significantly higher in TOV112 and SKOV3 cells. It has been proposed that OC cells shed from the primary tumor aggregate as spheroids in the ascites, maintain cellular contacts and survive in suspension. To mimic ovarian tumor cell dissemination through the ascites and to evaluate the role of the cadherin “switch” in this process, cell lines were grown under anchorage-independent conditions. The aggregates number/area was analyzed, being the SKOV3 spheroids the most compacted. When Ecad, Ncad and EMT markers expression was determined similar findings were obtained when spheroids were compared to monolayers, suggesting an intrinsic cell gene expression pattern rather than a response to a cell culture growth condition. The OC spheroids survival was assessed by estimating cell death, finding a positive correlation between high Ncad levels and cell aggregates with low% cell death. Spheroid adhesion/dissemination in extracellular matrices and 3D-spheroid matrigel assays were done to assess invasion at a secondary site. Spheroids from cells with mesenchymal/intermediate mesenchymal phenotypes adhered to extracellular matrices and invaded more than cells with intermediate epithelial/epithelial phenotypes. Finally, Ecad/Ncad expression studies done on primary cultures derived from tumor and ascitic cells from patients with OC revealed a diminished Ecad and a higher Ncad expression in ascitic cells compared to primary tumor cells. Altogether, the data here presented reveals an association between OC cell aggressiveness and a mesenchymal-like molecular profile; and it depends on the expression of Ecad and Ncad markers.
Citation Format: Marina Rosso, Blanca Majem, Laura Devis, Lara Lapyckyj, Marta Llauradó, Lucía Lanau, María Florencia Abascal, María Laura Matos, María José Besso, Josep Castellví, Jose Luís Sanchez-Iglesias, Asunción Pérez-Benavente, Antonio Gil-Moreno, Jaume Reventós, Marina Rigau, Mónica Vazquez-Levin. Cadherin “switch” and ovarian cancer: Studies using in vitro models and patient samples. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4093. doi:10.1158/1538-7445.AM2015-4093
Collapse
Affiliation(s)
- Marina Rosso
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Blanca Majem
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Laura Devis
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Lara Lapyckyj
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Marta Llauradó
- 3Faculty of Medicine, University of British Columbia, Vancouver, Canada
| | - Lucía Lanau
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - María Florencia Abascal
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - María Laura Matos
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - María José Besso
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Josep Castellví
- 4Department of Pathology, Vall Hebron University Hospital, Barcelona, Spain
| | | | | | - Antonio Gil-Moreno
- 5Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | - Jaume Reventós
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Marina Rigau
- 2Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Mónica Vazquez-Levin
- 1Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| |
Collapse
|
15
|
Majem B, Rigau M, Reventós J, Wong DT. Non-coding RNAs in saliva: emerging biomarkers for molecular diagnostics. Int J Mol Sci 2015; 16:8676-98. [PMID: 25898412 PMCID: PMC4425103 DOI: 10.3390/ijms16048676] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Revised: 04/02/2015] [Accepted: 04/08/2015] [Indexed: 01/05/2023] Open
Abstract
Saliva is a complex body fluid that comprises secretions from the major and minor salivary glands, which are extensively supplied by blood. Therefore, molecules such as proteins, DNA, RNA, etc., present in plasma could be also present in saliva. Many studies have reported that saliva body fluid can be useful for discriminating several oral diseases, but also systemic diseases including cancer. Most of these studies revealed messenger RNA (mRNA) and proteomic biomarker signatures rather than specific non-coding RNA (ncRNA) profiles. NcRNAs are emerging as new regulators of diverse biological functions, playing an important role in oncogenesis and tumor progression. Indeed, the small size of these molecules makes them very stable in different body fluids and not as susceptible as mRNAs to degradation by ribonucleases (RNases). Therefore, the development of a non-invasive salivary test, based on ncRNAs profiles, could have a significant applicability to clinical practice, not only by reducing the cost of the health system, but also by benefitting the patient. Here, we summarize the current status and clinical implications of the ncRNAs present in human saliva as a source of biological information.
Collapse
Affiliation(s)
- Blanca Majem
- Research Unit in Biomedicine and Translational Oncology, Lab 209, Collserola Building, Vall Hebron Research Institute (VHIR) and University Hospital, Pg. Vall Hebron 119-129, 08035 Barcelona, Spain.
| | - Marina Rigau
- Research Unit in Biomedicine and Translational Oncology, Lab 209, Collserola Building, Vall Hebron Research Institute (VHIR) and University Hospital, Pg. Vall Hebron 119-129, 08035 Barcelona, Spain.
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational Oncology, Lab 209, Collserola Building, Vall Hebron Research Institute (VHIR) and University Hospital, Pg. Vall Hebron 119-129, 08035 Barcelona, Spain.
- IDIBELL-Bellvitge Biomedical Research Institute & Universitat Internacional de Catalunya, 08908 Barcelona, Spain.
| | - David T Wong
- Center for Oral/Head & Neck Oncology Research, University of California, Los Angeles, CA 90095, USA.
| |
Collapse
|
16
|
Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J, Díaz-Feijoo B, Pérez-Benavente A, Colás E, Olivan M, Doll A, Alameda F, Matias-Guiu X, Moreno-Bueno G, Carey MS, Del Campo JM, Gil-Moreno A, Reventós J, Rigau M. MicroRNAs as prognostic markers in ovarian cancer. Mol Cell Endocrinol 2014; 390:73-84. [PMID: 24747602 DOI: 10.1016/j.mce.2014.03.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 02/09/2014] [Accepted: 03/25/2014] [Indexed: 01/18/2023]
Abstract
Ovarian cancer (OC) is the most lethal gynecological malignancy among women. Over 70% of women with OC are diagnosed in advanced stages and most of these cases are incurable. Although most patients respond well to primary chemotherapy, tumors become resistant to treatment. Mechanisms of chemoresistance in cancer cells may be associated with mutational events and/or alterations of gene expression through epigenetic events. Although focusing on known genes has already yielded new information, previously unknown non-coding RNAs, such as microRNAs (miRNAs), also lead insight into the biology of chemoresistance. In this review we summarize the current evidence examining the role of miRNAs as biomarkers of response and survival to therapy in OC. Beside their clinical implications, we also discuss important differences between studies that may have limited their use as clinical biomarkers and suggest new approaches.
Collapse
Affiliation(s)
- Marta Llauradó
- Faculty of Medicine, University of British Columbia, Vancouver, Canada; Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Blanca Majem
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Tatiana Altadill
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Lucia Lanau
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Josep Castellví
- Department of Pathology, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Silvia Cabrera
- Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | - Javier De la Torre
- Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | - Berta Díaz-Feijoo
- Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | | | - Eva Colás
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Mireia Olivan
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Andreas Doll
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| | - Francesc Alameda
- Department of Pathology, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Xavier Matias-Guiu
- Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Lleida, Spain
| | - Gema Moreno-Bueno
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, 28029, Madrid, Spain & Fundación MD Anderson Internacional, 28033 Madrid, Spain
| | - Mark S Carey
- Division of Gynecologic Oncology, University of British Columbia and BC Cancer Agency, Vancouver, BC, Canada
| | - Josep Maria Del Campo
- Division of Gynecology and Head and Neck, Department of Oncology, Vall Hebron University Hospital, Barcelona, Spain
| | - Antonio Gil-Moreno
- Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain; Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain; Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain; Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain; IDIBELL- Bellvitge Biomedical Research Institute, Barcelona, Spain.
| | - Marina Rigau
- Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain
| |
Collapse
|
17
|
Garcia M, Velez R, Romagosa C, Majem B, Pedrola N, Olivan M, Rigau M, Guiu M, Gomis RR, Morote J, Reventós J, Doll A. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int 2014; 113:E164-77. [DOI: 10.1111/bju.12503] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Marta Garcia
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
| | - Roberto Velez
- Universitat Autònoma de Barcelona; Barcelona Spain
- Orthopaedic Surgery and Traumatology Department; Vall d'Hebron University Hospital; Barcelona Spain
| | - Cleofé Romagosa
- Universitat Autònoma de Barcelona; Barcelona Spain
- Department of Pathology; Vall d'Hebron University Hospital; Barcelona Spain
| | - Blanca Majem
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
| | - Núria Pedrola
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
| | - Mireia Olivan
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Orthopaedic Surgery and Traumatology Department; Vall d'Hebron University Hospital; Barcelona Spain
| | - Marina Rigau
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
| | - Marc Guiu
- Oncology Programme; Institute for Research in Biomedicine (IRB-Barcelona); Barcelona Spain
| | - Roger R. Gomis
- Oncology Programme; Institute for Research in Biomedicine (IRB-Barcelona); Barcelona Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA); Barcelona Spain
| | - Juan Morote
- Universitat Autònoma de Barcelona; Barcelona Spain
- Department of Urology; Vall d'Hebron University Hospital; Barcelona Spain
| | - Jaume Reventós
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
- Department of Basic Science; International University of Catalonia; Barcelona Spain
| | - Andreas Doll
- Research Unit in Biomedicine and Translational and Pediatric Oncology; Research Institute Vall d'Hebron University Hospital (VHIR); Barcelona Spain
- Department of Basic Science; International University of Catalonia; Barcelona Spain
| |
Collapse
|
18
|
Lanau L, Rigau M, Majem B, Altadill T, Castellví J, Sánchez-Iglesias JL, Pérez-Benavente A, Cabrera S, García A, Xercavins J, Campo JMD, Gil-Moreno A, Ruiz A, Reventós J, Llauradó M. Abstract B15: Unveiling the mechanism of ovarian cancer dissemination through a comparative study among primary tumors, ascites and metastases. Clin Cancer Res 2013. [DOI: 10.1158/1078-0432.ovca13-b15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction & Objectives: Epithelial ovarian cancer (OC) is the most lethal gynecological malignancy and the fifth cause of cancer deaths in women in the western world. Largely asymptomatic, OC is frequently detected at late stage (75-80%). Five-year survival rate for women with advanced stage disease is less than 20%, while the cure rate is almost 90% when are diagnosed at early stages. Epithelial OC metastasizes by direct extension from the ovary seeding the cells into the peritoneal wall and to neighbouring organs. Our aim is to study the OC dissemination comparing human paired ovarian primary tumors, ascites and metastases.
Material & Methods: Fresh ovarian primary tumor, ascites and peritoneal metastases from patients suffering advanced serous OC were collected at the surgery room and processed for further analysis. Formalin-fixed paraffin-embedded (FFPE) tissues were collected from the Pathology Department for further immunohistochemical analysis. Discovery phase: We determined the global gene expression profile of 5 fresh-paired samples (primary tumor, ascites and metastases) by microarray analysis. Validation phase: We analysed mRNA and protein levels from 10 unpaired fresh samples by RTqPCR and Western-blot, respectively. We further evaluated protein expression by immunohistochemistry from 10-paired tumor and metastasis FFPE-samples.
Results: GREM1 was shown to be upregulated in metastases versus ascites and in metastases versus primary tumors. FABP4 and INHBA were significantly overexpressed in metastases when compared to primary tumors. INHBA and FABP4 were validated at RNA and protein level, whereas GREM1 only at RNA level.
Conclusions: The present study highlights the role of previously unknown candidates in OC dissemination that might be used as tumor biomarkers, to clinically monitor the progression of the disease, or as target therapies, to block the OC dissemination.
Citation Format: Lucia Lanau, Marina Rigau, Blanca Majem, Tatiana Altadill, Josep Castellví, José-Luis Sánchez-Iglesias, Assumpció Pérez-Benavente, Silvia Cabrera, Angel García, Jordi Xercavins, Josep-Maria Del Campo, Antonio Gil-Moreno, Anna Ruiz, Jaume Reventós, Marta Llauradó. Unveiling the mechanism of ovarian cancer dissemination through a comparative study among primary tumors, ascites and metastases. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr B15.
Collapse
Affiliation(s)
- Lucia Lanau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Marina Rigau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Blanca Majem
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Tatiana Altadill
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Josep Castellví
- 2Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | | | - Assumpció Pérez-Benavente
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Silvia Cabrera
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Angel García
- 2Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Jordi Xercavins
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Josep-Maria Del Campo
- 4Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Barcelona, Spain
| | - Antonio Gil-Moreno
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Anna Ruiz
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Jaume Reventós
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Marta Llauradó
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| |
Collapse
|
19
|
Altadill T, Rigau M, Majem B, Lanau L, Castellví J, García Á, Pérez-Benavente A, Sánchez JL, Cabrera S, Xercavins J, Campo JMD, Gil-Moreno A, Llauradó M, Reventós J. Abstract A28: Analyses of FOXM1 isoforms in ovarian cancer. Clin Cancer Res 2013. [DOI: 10.1158/1078-0432.ovca13-a28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction & Objectives: Epithelial ovarian cancer (OC) is the most lethal gynaecological malignancy and the fifth leading cause of cancer death in women in the Western world. Forkhead box M1 (FOXM1) transcription factor was already been described to be overexpressed in various malignancies, playing a key role in cell-cycle progression, chromosomal segregation and genomic stability, and oxidative stress. Moreover, it can also promote drug resistance to herceptin, paclitaxel and cisplatin in breast cancer cells. A recent report from our group has shown, for the first time, that FOXM1 is also overexpressed in OC, being associated with tumor grade. This result seem to indicate an interesting role of this molecule in the progression and resistance to therapy in OC. Our aim is to characterize FOXM1 isoforms in OC through the use of human tissue samples.
Material & Methods: Fresh ovarian primary tumors, ascites and peritoneal metastases from patients suffering advanced serous OC were collected from surgery room and processed for microarray analysis to detect FOXM1 expression levels. FOXM1 isoforms were analysed at mRNA expression level by using RTqPCR in a set of new frozen tissue samples.
Results: We found that FOXM1 overexpression is increased in OC peritoneal metastases. Now, we are characterizing the isoforms of FOXM1 in primary, ascites and metastatic tumors. Nevertheless, more samples need to be analysed in order to have conclusive results.
Conclusions: The present study highlights the role of FOXM1 isoforms in OC dissemination and pursues the idea to elucidate the biologic role of FOXM1 in OC tumorigenesis.
Citation Format: Tatiana Altadill, Marina Rigau, Blanca Majem, Lucia Lanau, Josep Castellví, Ángel García, Assumpció Pérez-Benavente, José Luis Sánchez, Silvia Cabrera, Jordi Xercavins, Josep Maria del Campo, Antonio Gil-Moreno, Marta Llauradó, Jaume Reventós. Analyses of FOXM1 isoforms in ovarian cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr A28.
Collapse
Affiliation(s)
- Tatiana Altadill
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| | - Marina Rigau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| | - Blanca Majem
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| | - Lucia Lanau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| | - Josep Castellví
- 2Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Ángel García
- 2Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | | | - José Luis Sánchez
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Silvia Cabrera
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Jordi Xercavins
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Josep Maria del Campo
- 4Department of Medical Oncology, Gynecological and Head and Neck Tumors, Vall d'Hebron Institute of O, Barcelona, Spain,
| | - Antonio Gil-Moreno
- 3Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Marta Llauradó
- 5Medical University, University of British Columbia, Vancouver, Canada
| | - Jaume Reventós
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Spain,
| |
Collapse
|
20
|
Rigau M, Majem B, Altadill T, Lanau L, Sánchez-Iglesias JL, Castellví J, Pérez-Benavente A, Cabrera S, García A, Xercavins J, Alameda F, Matias-Guiu X, Gil-Moreno A, Campo JMD, Llauradó M, Reventós J. Abstract A56: Identification of a micro RNA profile to predict response to therapy and improve patient survival in ovarian cancer. Clin Cancer Res 2013. [DOI: 10.1158/1078-0432.ovca13-a56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction & Objectives: Ovarian cancer (OC) is the leading cause of death among gynecological malignancies in developed countries. The standard treatment is surgery plus platinum-paclitaxel (CP/TX) chemotherapy. Nevertheless, 70% of these patients are diagnosed in advanced stages, and, among those, 75% will recur, become resistant to therapies and die. We believe that an improvement in OC survival might be related with an early identification of those patients, since long survival (SV) is related to chemosensitivity. Our aim is to identify an expression profile of micro RNAs (miRNAs) associated with SV of patients with advanced OC.
Material & Methods: Formalin-fixed paraffin-embedded (FFPE) primary tumor tissues from late stage (III/IV) OC patients were collected at the time of surgery for the study. All patients were treated with optimal surgery and standard chemotherapy (CP/TX; after surgery). Samples were divided into two groups; (a) patients with “long SV” (SV>10 years after diagnosis) and (b) patients with “short SV”. The identification of miRNAs associated with each profile of SV was performed using TaqMan Array MicroRNA microfluidic cards in 30 patients.
Results: The identification phase has shown that the majority of the miRNAs appeared to be down-regulated in the group of “short SV” versus the “long SV”. A validation phase in a new group of tumor tissue samples is ready to validate the promising miRNA candidates that seem to be associated with the resistant (short SV) and the sensitive (long SV) profiles.
Conclusions: The ability to identify markers associated with “long SV” in patients with advanced OC could allow transforming the impact of the disease through the reduction of chemotherapy treatments and the reduction of unnecessary health care costs. Moreover, it could permit the generation of knowledge applicable to the future development of new therapies for the “short SV” since they are supposed to be resistant to the therapy.
Citation Format: Marina Rigau, Blanca Majem, Tatiana Altadill, Lucia Lanau, José-Luis Sánchez-Iglesias, Josep Castellví, Assumpció Pérez-Benavente, Silvia Cabrera, Angel García, Jordi Xercavins, Francesc Alameda, Xavier Matias-Guiu, Antonio Gil-Moreno, Josep-Maria Del Campo, Marta Llauradó, Jaume Reventós. Identification of a micro RNA profile to predict response to therapy and improve patient survival in ovarian cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr A56.
Collapse
Affiliation(s)
- Marina Rigau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Blanca Majem
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Tatiana Altadill
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Lucia Lanau
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | | | - Josep Castellví
- 3Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Assumpció Pérez-Benavente
- 2Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Silvia Cabrera
- 2Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Angel García
- 3Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Jordi Xercavins
- 2Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Francesc Alameda
- 4Pathology Department, Hospital del Mar, Barcelona, Barcelona, Spain,
| | - Xavier Matias-Guiu
- 5Pathology Department, Hospital Arnau de Vilanova, Lleida, Lleida, Spain,
| | - Antonio Gil-Moreno
- 2Department of Gynecological Oncology, Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain,
| | - Josep-Maria Del Campo
- 6Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Barcelona, Spain
| | - Marta Llauradó
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| | - Jaume Reventós
- 1Research Unit in Biomedicine and Translational Oncology, Research Institute Vall d'Hebron University, Barcelona, Barcelona, Spain,
| |
Collapse
|
21
|
Llauradó M, Ruiz A, Majem B, Ertekin T, Colás E, Pedrola N, Devis L, Rigau M, Sequeiros T, Montes M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellví J, Garcia A, Ramón y Cajal S, Moreno G, Alameda F, Vázquez-Levin M, Palacios J, Prat J, Doll A, Matías-Guiu X, Abal M, Reventós J. Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol 2012; 358:244-55. [PMID: 22037169 DOI: 10.1016/j.mce.2011.10.003] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Revised: 09/30/2011] [Accepted: 10/04/2011] [Indexed: 12/31/2022]
Abstract
Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.
Collapse
Affiliation(s)
- Marta Llauradó
- Biomedical Research Unit, Vall d'Hebron Research Institute and University Hospital, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Llauradó M, Majem B, Castellví J, Cabrera S, Gil-Moreno A, Reventós J, Ruiz A. Analysis of Gene Expression Regulated by the ETV5 Transcription Factor in OV90 Ovarian Cancer Cells Identifies FOXM1 Overexpression in Ovarian Cancer. Mol Cancer Res 2012; 10:914-24. [DOI: 10.1158/1541-7786.mcr-11-0449] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llauradó M, Colás E, Pedrola N, Montes M, Sequeiros T, Ertekin T, Majem B, Planas J, Ruiz A, Abal M, Sánchez A, Morote J, Reventós J, Doll A. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate 2011; 71:1736-45. [PMID: 21520154 DOI: 10.1002/pros.21390] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Accepted: 03/07/2011] [Indexed: 12/18/2022]
Abstract
BACKGROUND Several studies have demonstrated the usefulness of monitoring an RNA transcript, such as PCA3, in post-prostate massage (PM) urine for increasing the specificity of prostate-specific antigen (PSA) in the detection of prostate cancer (PCa). However, a single marker may not necessarily reflect the multifactorial nature of PCa. METHODS We analyzed post-PM urine samples from 154 consecutive patients, who presented for prostate biopsies because of elevated serum PSA (>4 ng/ml) and/or abnormal digital rectal exam. We tested whether the putative PCa biomarkers PSMA, PSGR, and PCA3 could be detected by quantitative real-time PCR in post-PM urine sediment. We combined these findings to test if a combination of these biomarkers could improve the specificity of actual diagnosis. Afterwards, we specifically tested our model for clinical usefulness in the PSA diagnostic "gray zone" (4-10 ng/ml) on a target subset of 82 men with no prior biopsy. RESULTS By univariate analysis, we found that the PSMA, PSGR, and PCA3 scores were significant predictors of PCa. Using a multiplex model, the area under the multi receiver-operating characteristic curve was 0.74 versus 0.82 in the diagnostic "gray zone." Fixing the sensitivity at 96%, we obtained a specificity of 34% and 50% in the gray zone. CONCLUSIONS Taken together, these results provide a strategy for the development of a more accurate model for PCa diagnosis. In the future, a multiplexed, urine-based diagnostic test for PCa with a higher specificity, but the same sensitivity as the serum-PSA test, could be used to determine better which patients should undergo biopsy.
Collapse
Affiliation(s)
- Marina Rigau
- Research Unit in Biomedicine and Translational and Pediatric Oncology, Vall d'Hebron Research Institute, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|